New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
19:16 EDTNKE, TIBX, RHT, WWAY, RIMM, MU, HEBOn The Fly: After Hours Movers
UP AFTER EARNINGS: Nike (NKE), up 5%... Tibco Software (TIBX), up 4.7%... Red Hat (RHT), up 5.6%... ALSO HIGHER: Westway Group (WWAY), up 8% after an affiliate of EQT Infrastructure agreed to acquire the company for $6.70 per share... DOWN AFTER EARNINGS: Research in Motion (RIMM), down 10%... Micron Technology (MU), down 3.2%... ALSO LOWER: Hemispherx BioPharma (HEB), down 24% after Bloomberg reported that an FDA advisory panel voted against recommending approval for the company's drug Ampligen.
News For NKE;TIBX;RHT;WWAY;RIMM;MU;HEB From The Last 14 Days
Check below for free stories on NKE;TIBX;RHT;WWAY;RIMM;MU;HEB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 17, 2014
12:01 EDTNKENike suspends contract with Adrian Peterson
Subscribe for More Information
10:00 EDTNKEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:58 EDTRHTRed Hat October volatility elevated into Q2 and outlook
Red Hat September call option implied volatility is at 92, October is at 36, December is at 29; compared to its 26-week average of 30 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on September 18.
07:30 EDTNKENike September weekly volatility elevated into Q1 and outlook
Subscribe for More Information
September 16, 2014
16:34 EDTNKENike assumed with a Neutral at Piper Jaffray
Target $77.
09:36 EDTMUActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX TSLA YHOO FB PBR MU AA TWTR WMT
September 15, 2014
11:56 EDTMUStocks with call strike movement; MU GILD
Subscribe for More Information
08:44 EDTHEBHemispherx Ampligen induces cross-reactive antibody formation
Subscribe for More Information
September 14, 2014
18:10 EDTMUMicron looks to expand to autos and wearables, WSJ says
Subscribe for More Information
September 12, 2014
14:24 EDTTIBXTibco Software September volatility elevated into Q3 and outlook
Subscribe for More Information
September 11, 2014
11:14 EDTRHTGoogle hires former Red Hat CTO Brian Stevens, GigaOM reports
Subscribe for More Information
September 10, 2014
14:35 EDTTIBXTibco Software September volatility elevated into Q3 and outlook
Subscribe for More Information
10:44 EDTMUMicron mentioned positively at Raymond James
08:35 EDTHEBHemispherx expands Ebola collaborative research agreement with governments
Hemispherx Biopharma announced that it expanded its Collaborative Research Agreement to test Alferon, the only multi-species, natural alpha interferon, or IFN, commercially approved in the U.S. and Ampligen®, an experimental drug, to be evaluated against the deadly Ebola virus also under the DEA, or Data Exchange Agreement, Annex for Medical Preparedness and Bio-Defense Agreement between the Swiss Surgeon General and the US Department of Defense. The World Health Organization has warned that "The Ebola outbreak will affect more than 20,000 people in West Africa and might spread to more countries, indicating a clinical emergency all over the world."
07:56 EDTRHTRed Hat October volatility elevated into Q2 and outlook
Subscribe for More Information
07:24 EDTRHTRed Hat coverage assumed with a Neutral at MKM Partners
Subscribe for More Information
September 9, 2014
07:22 EDTMURaymond James to hold a conference
North American Equities Conference to be held in London, England on September 9.
06:20 EDTNKEForrester: Apple could sell 10M iWatches this year, FT reports
Subscribe for More Information
September 8, 2014
11:05 EDTRHTOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
08:43 EDTHEBHemispherx, USAMRIID to collaborate in studying Alferon, Ampligen
Hemispherx Biopharma announced that the company and United States Army Medical Research Institute of Infectious Diseases, or USAMRIID, scientists have agreed to test Alferon, the only multi-species, natural alpha interferon, or IFN, commercially approved in the U.S. and Ampligen, an experimental drug, to be evaluated against the deadly Ebola virus, which has been and remains a major focus of efforts at USAMRIID, a unit of the Department of Defense responsible for medical biological defense research. A key component of innate immune responses is activation of the Toll-like receptors, or TLRs. TLR3 activation by dsRNA is an essential response element to viral infection. Block TLR3 activation and an essential element of the innate immune response is disarmed. Ampligen, Poly I:Poly C12U was designed as an IFN inducer and has demonstrated antiviral activity in a wide variety of DNA and RNA viruses in pre-clinical testing. Replenishing an Ebola patient's natural interferon with Alferon and restoring that patient's innate immune response by Ampligen's overcoming the Ebola blocking mechanisms could potentially reduce the morbidity and mortality of Ebola virus disease.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use